Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bi... Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. Mostrar más
Icovamenib & BMF-650 (oral small molecule GLP-1) are the cornerstones of the metabolic franchiseBiomea preparing icovamenib for late-stage clinical development2025 corporate update to be...
New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight reduction and 43% increase in lean muscle mass...
REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral...
Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient populationBest response...
REDWOOD CITY, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral...
In preclinical experiments, icovamenib enhanced beta cell function and responsiveness of human islets to GLP-1-based therapies. These effects were associated with an increase in the expression...
Preliminary data supports BMF-500’s potential as a transformative therapy for patients with FLT3 mutated relapsed or refractory (R/R) acute leukemiaBMF-500 showed a favorable safety and...
REDWOOD CITY, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral...
| Período † | Variación(Ptos) | Variación % | Apertura | Precio Máximo | Precio Mínimo | Avg. Vol. diario | Precio Promedio Ponderado | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.315 | 8.30039525692 | 3.795 | 4.32 | 3.675 | 1198492 | 4.05090005 | CS |
| 4 | -1.66 | -28.7694974003 | 5.77 | 6.06 | 3.64 | 1307931 | 4.21376154 | CS |
| 12 | -7.54 | -64.7210300429 | 11.65 | 12.85 | 3.64 | 888985 | 6.37487363 | CS |
| 26 | -1.26 | -23.4636871508 | 5.37 | 13.07 | 3.64 | 823976 | 7.15927746 | CS |
| 52 | -10.95 | -72.7091633466 | 15.06 | 20.21 | 3.64 | 996411 | 9.4071117 | CS |
| 156 | -4.03 | -49.5085995086 | 8.14 | 43.69 | 2.84 | 651320 | 14.53005254 | CS |
| 260 | -15.89 | -79.45 | 20 | 43.69 | 2.84 | 548509 | 14.4529643 | CS |
Monksdream
4 meses hace
Zraced1
8 meses hace
giveit2me
1 año hace
Invest-in-America
2 años hace
Invest-in-America
2 años hace
TheFinalCD
2 años hace
Invest-in-America
2 años hace
Bbradley8
2 años hace
Parece que no se ha autenticado. Haga click al botón de abajo para iniciar la sesión y ver los símbolos recientemente consultados.
Soporte: (55) 4170 8128 | soporte@advfn.mx
Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones
Hot Features
Premium
